

From: [Trials](#)
To: [Lovsin, James](#)
Cc: [Berghoff, Paul](#); [Suggs, James V.](#); [docketing@mbhb.com](#); [Rigel IPR Group](#); [tfink@omm.com](#); [jeng@kslaw.com](#); [VYen@KSLAW.com](#); [EDiamond@KSLAW.com](#); [hsayeed@omm.com](#); [jli@omm.com](#); [bhaber@omm.com](#); [Trials](#)
Subject: RE: IPR2022-01423 - Joint request to file a joint motion to dismiss and/or terminate the petition
Date: Monday, December 19, 2022 2:08:57 PM

Counsel,

The parties are authorized to file a joint motion to terminate IPR2022-01423. The parties are reminded of their obligation under 37 C.F.R. § 42.74 to file a copy of the settlement agreement and any collateral agreements (including any licensing agreements) with the Board. In the motion, the parties should also include a statement that there are no other agreements, oral or written, between the parties made in connection with, or in contemplation of, the termination of the proceeding, assuming such a statement is correct. If the parties cannot make such a statement, the other agreement(s) should be filed pursuant to 37 C.F.R. § 42.74.

The parties also are authorized to file a joint request to treat the settlement agreement as business confidential information. To have the settlement agreement treated as business confidential information under 37 C.F.R. § 42.74(c), the parties must file the confidential settlement agreement electronically in the Patent Trial and Appeal Case Tracking System (PTACS) as an exhibit in accordance with the instructions provided on the Board's website (uploading as "Parties and Board Only"). The parties are directed to FAQ G2 on the Board's website at https://www.uspto.gov/sites/default/files/documents/p-tacts_faqs_20221007.pdf for guidance on how to file their settlement agreement as confidential. Please submit the joint motion and joint request no later than January 16, 2023.

Regards,

Esther Goldschlager
Supervisory Paralegal Specialist
Patent Trial & Appeal Board
U.S. Patent & Trademark Office
(571) 272-7822

From: Lovsin, James <Lovsin@mbhb.com>
Sent: Sunday, December 18, 2022 2:35 PM
To: Trials <Trials@USPTO.GOV>
Cc: Berghoff, Paul <Berghoff@mbhb.com>; Suggs, James V. <suggs@mbhb.com>; docketing@mbhb.com; Rigel IPR Group <RigelIPR@mbhb.com>; tfink@omm.com; jeng@kslaw.com; VYen@KSLAW.com; EDiamond@KSLAW.com; hsayeed@omm.com; jli@omm.com; bhaber@omm.com
Subject: IPR2022-01423 - Joint request to file a joint motion to dismiss and/or terminate the petition

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Dear Honorable Board,

The parties to IPR2022-01423 have reached a settlement that addresses this proceeding. Accordingly, Petitioner Rigel Pharmaceuticals, Inc. and Patent Owner Servier Pharmaceuticals LLC seek authorization to file a joint motion to dismiss and/or terminate the petition pursuant to 37 C.F.R. §§ 42.71(a) and 42.72. The parties can make themselves available for a conference call, should the Board find it helpful.

Respectfully submitted,

James Lovsin
Counsel for Petitioner, Rigel Pharmaceuticals, Inc.